CEO Peter Buhl will present the data at the ASCO meeting taking place June 2-6 online and in person at the McCormick Place in Chicago. The poster shows the final data from a phase 2 study evaluating the ability of the DRP[®] companion diagnostic for cisplatin to prospectively identify patients with metastatic breast cancer that are likely to respond to treatment with LiPlaCis[®], a targeted liposomal formulation of cisplatin. The study was  conducted  in collaboration with investigators at hospitals in Denmark. CHOSA Oncology has inlicensed worldwide rights to the LiPlaCis program and its DRP which together is named iCIP™.

The poster presentation details are as follows:

Poster Title: "Predictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancer."
Authors: Nielsen, D., Jakobsen, E,H., Langkjer, S.T., Danoe, H., Balslev, E., Knoop, A., … Lassen, U.N.
Abstract Number: 3130
Session Title: Developmental Therapeutics-Molecularly Targeted Agents and Tumor Biology
Date and Time: 6/3/2023, 8:00 AM-11:00 AM local time

This disclosure contains information that Chosa Oncology AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 11-04-2023 13:00 CET.